10x Genomics (TXG) Tops Q4 EPS by 9c, provides guidance

10x Genomics (NASDAQ: TXG) reported Q4 EPS of ($0.13), $0.09 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $166 million versus the consensus estimate of $157.73 million.

GUIDANCE:

10x Genomics sees FY2026 revenue of $600-625 million, versus the consensus of $611.8 million.

For earnings history and earnings-related data on 10x Genomics (TXG) click here.

You May Also Be Interested In

• FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
• Tutor Perini prices $400M in senior notes to refinance debt
• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance